Clinical Trials Sponsored by Merck Serono Co., Ltd., China

Total 891 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

Melanoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Nonsmall-cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Recurrent / Metastatic Nasopharyngeal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Endometrial Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB3824 in Subjects With Advanced Cancer

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

Type 2 Diabetes

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Advanced Solid Tumors and Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors

Terminal Malignant Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Advanced Renal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

Chronic Hepatitis B

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Pharmacokinetic

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Gastric Cancer | Non-small Cell Lung Cancer | Colo-rectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Metastatic Breast Cancer | Metastatic Gastric Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase I Clinical Trial of Bevacizumab Injection

Cervical Cancer | Glioblastoma | Ovarian Cancer | Lung Cancer | Rectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects

Recurrent/Metastatic Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Chronic Myelogenous Leukemia - Chronic Phase

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics

Advanced Solid Tumor or Hematologic Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis

Bone Metastatic Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Safety and Effectiveness

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Relapsed / Refractory Mantle Cell Lymphoma (MCL)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Relapsed / Refractory Follicular Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Advanced Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Advanced Head, Neck and Chest Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Multiple Myeloma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Anlotinib in Subjects With Advanced Malignancy

Advanced Malignancy

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

ALK-positive NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）

Squamous Cell Carcinoma of the Head and Neck

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China

3

Subscribe